Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1994-12-20
1999-09-14
Chan, Christina Y.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
4241301, 4241311, 4241331, 4241361, 4241391, 4241411, 4241431, 4241441, 4241531, 5303871, 5303872, 5303873, 5303879, 5303881, 5303882, 53038822, 53038873, 53038875, A61K 39395, C07K 1628
Patent
active
059519827
ABSTRACT:
The present invention relates to a method of reducing or suppressing an immune response with antibodies specific for variants of the glycoprotein CD44. The invention further relates to a method of preventing or treating an immunoregulatory disorder or disease with these antibodies.
REFERENCES:
Weiss, J.M. et al., "An Essential Role for CD44 Variant Isoforms in Epidermal Langerhans Cell and Blood Dendritic Cell Function," J. Cell. Biol. 137:1137-1147 (Jun. 1997).
Tolg, C. et al., "Splicing Choice from Ten Variant Exons Establishes CD44 Variability," Nucl. Acids Res. 21:1225-1229 (1993).
Claas, C. et al., "Developmentally Regulated Expression of Metastasis-Associated Antigens in the Rat," Cell Growth Differat. 7: 663-678 (1996).
Sandmaier et al. Blood 91: 3494-3502 (1998).
Brennan Clin. Exp. Immunol. 97: 1-3 (1994).
Wittig et al. Immunology Letters 57: 217-223 (1997).
I. Albeldo Faseb J. 8: 504-512 (1994).
Cobbold et al., Nature 312?: 548-551 (1984).
Galuzzo et al. Eur. J. Immunol. 25: 2932-2939 Given at interview (#28) (1995).
Ward et al. Therapeutic Immunology 1: 165-171 (1994).
Zoller et al. Onkologie 17: 114-122 (1994).
Mountain et al. Biotech & Gen. Eng. Rev. 10: pp. 10-11 (1993).
Edgington et al. Biotechnology 10: 383-389 (1992).
Shaffer Biotechnology News Watch p. 9 Oct. 4, 1993.
Borre Breck et al. Immunol. Today 14: 477-479 (1993).
Joliffe Intern Rev. Immunol. 10: 241-50 (1993).
Koopman et al. J Exp Med 177: 897-904 (1993).
Harris et al. Tibtech 11: 42-44 (1993).
Waldmann Science 252: 1657-1662 (1991).
Vitetta et al. Ann. Rev. Immunol. 9: 193-217 (1991).
Hofmann et al. Cancer Res. 51: 5292-5297 (1991).
Stamenkovic et al. Embo J. 10: 343-348 (1991).
Neu, S., et al., "Expression Of CD44 Isoforms By Highly Enriched CD34-Positive Cells In Cord Blood, Bone Marrow And Leukaphereses," Bone Marrow Transplantation, 20:593-598 (1997).
Griffioen, A.W, et al., "Expression of CD44 Splice Variants During Lymphocyte Activation and Tumor Progression," Cell Adhesion and Communication, 2:195-200, (1994).
Levesque, M.C., et al., "In Vitro Culture Of Human Peripheral Blood Monocytes Induces Hyaluronan Binding And Up-Regulates Monocyte Variant CD44 Isoform Expression," J. Immunol. 156:1157-1565, (1996).
Pals, S.T., et al., "CD44 Splice Variants: Expression During Lymphocyte Activation and Tumor Progression," Behring Inst. Mitt., 92:273-277 (1993).
Camp, R.L. et al., "High levels of CD44 expression distinguish virgin from antigen-primed B cells", J. Exp. Med. 173:763-766 (Mar. 1991).
Gunthert, U. et al., "A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells", Cell 65:13-24 (Apr. 5, 1991).
Huet, S. et al., "CD44 contributes to T cell activation", J. Immunol. 143(3):798-801 (Aug. 1, 1989).
Jalkanen, S. et al., "Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells", J. Cell Biol. 105:983-990 (Aug. 1987).
Jalkanen, S.T. et al., "A lymphoid cell surface glycoprotein involved in endothelial cell recognition and lymphocyte homing in man", Eur. J. Immunol. 16:1195-1202 (1986).
Jerne, N.K. & Nordin, A.A., "Plaque formation in agar by singele antibody-producing cells", Science 140:405 (Apr. 26, 1963).
Matzku, S. et al., "Antigenic differences between metastatic and nonmetastatic BSp73 rat tumor variants characterized by monoclonal antibodies", Cancer Research 49:1294-1299 (Mar. 1, 1989).
Reber, S. et al., "Retardation of metastatic tumor growth after immunization with metastatsis-specific monoclonal antibodies", Int. J. Cancer 46:919-927 (1990).
Shimizu, Y. et al., "Dual role of the CD44 molecule in T cell adhesion and activation", J. Immunol. 143(8):2457-2463 (Oct. 15, 1989).
Stamenkovic, I. et al., "A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family", Cell 56:1057-1062 (Mar. 24, 1989).
Zoller, M. & Andrighetto, G., "Comparison between the in Vitro activities of in Vivo-induced hapten-specific suppressor cells and supernatants of a hapten-specific suppressor hybridoma", Cellul. Immunol. 89:310-321 (1984).
Kavanaugh et al., Treatment of Refractory Rheumatoid Arthritis with Anti-CD54 Intercellular Adhesion Molecule-1 (ICAM-1) Monoclonal Antibody, Arthritis and Rheumatism, vol. 35.9, S43:53 (Sep. 1992).
Herrlich Peter
Ponta Helmut
Zoller Margot
Auerbach Jeffrey I
Boehringer Ingelheim Pharmaceuticals Inc.
Chan Christina Y.
Gambel Phillip
LandOfFree
Methods to suppress an immune response with variant CD44-specifi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods to suppress an immune response with variant CD44-specifi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to suppress an immune response with variant CD44-specifi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1507973